Company intelligence / Profile preview

Bonalive

Ownership: Private
Development stage: Commercial

Overview

Bonalive’s S53P4 bioactive glass products have over three decades of research support and more than 300 scientific publications. Clinical use spans orthopedic, trauma, spine surgeries, and chronic osteomyelitis. The company’s antibiotic-free approach to infection management has demonstrated efficacy in inhibiting bacterial growth while promoting natural bone regeneration. The company recently received FDA Breakthrough Device Designation for its granules product targeting microbial colonization protection.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceBiomaterial (bioactive glass)Non-pharmacological therapy (antibiotic-free infection management)
Industry: Implantable Medical Devices

Drug pipeline

3 assets

Bonalive granules

Commercial

Indications: Bone void filling, Bone infection

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bonalive.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bonalive.

Explore the full profile